Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Cervical Cancer

Join Larissa Lee, MD and Ursula Matulonis, MD from Dana-Farber Cancer Institute as they present their multidisciplinary expertise on a range of cases pertaining to cervical cancer.

In the United States, an estimated 12,360 new cases of cervical cancer will be diagnosed, and 4020 people are expected to die of the disease. Cervical cancer rates are decreasing among women in the United States, but incidence remains high among disparate populations. Additionally, cervical cancer is the fourth-most common cancer among women worldwide; 85% of cases occur in developing countries where the disease is a leading cause of cancer death in women. Persistent human papillomavirus (HPV) infection is the most important factor in the development of cervical cancer. Prognosis for women with cervical cancer depends on the extent of disease at the time of diagnosis. Although many cases of cervical cancer can be prevented or detected early via Pap and HPV testing, a significant proportion of eligible women do not receive screening, leading to cases of difficult-to-treat advanced disease and elevated mortality rates.

The availability of new targeted therapies (i.e., bevacizumab, a VEGF-targeted antiangiogenic agent) has led to clinical trial investigation of novel combination systemic therapy regimens for treating recurrent or metastatic disease. Based on these data, the FDA recently approved bevacizumab for use in combination with cisplatin/paclitaxel or topotecan/paclitaxel regimens to treat persistent, recurrent, or metastatic cervical cancer. Treatment of early-stage cervical cancer has also evolved in recent years. Clinical data over the past decade has provided added support for the safety and efficacy of conservative treatment approaches (i.e., fertility-sparing) for treating certain patients with early-stage cervical cancer. Lastly, continual advances in imaging and minimally invasive surgical techniques present clinicians with decisions regarding an expanding array of imaging techniques and surgical approaches.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss current options for the medical, radiologic, and surgical treatment of cervical cancer
  • Summarize the current and emerging clinical evidence for treating cervical cancer
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.57 ANCC contact hours
  • 0.50 Participation
Course opens: 
12/23/2015
Course expires: 
12/23/2016
Cost:
$0.00

Larissa Lee, MD
Dana-Farber Cancer Institute

Ursula Matulonis, MD
Dana-Farber Cancer Institute

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have disclosed the following relevant financial relationships:

Ursula Matulonis, MD
Genentech, Inc. – Scientific Advisor

The faculty listed below have no relevant financial relationships to disclose:

Larissa Lee, MD

NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Jillian Scavone, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date: December 23, 2015
Expiration date: December 23, 2016

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.57 contact hour. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Release date: December 23, 2015
Expiration date: December 23, 2016

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-15-159-H01-P

Release date: December 23, 2015
Expiration date: December 23, 2016

Available Credit

  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.57 ANCC contact hours
  • 0.50 Participation

Accreditation Period

Course opens: 
12/23/2015
Course expires: 
12/23/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing